A Review on Acotiamide
Journal of Pharmaceutical Research International · pp. 127–129 · Published 13 Dec 2021
10.9734/jpri/2021/v33i56A33894Abstract
Functional dyspepsia (FD) is mainly treated by drugs like H2 receptors antagonists, Proton pump inhibitors, prokinetics. A novel prokinetic drug to treat FD with 2 subtypes: Epigastric pain syndrome (EPS) & postprandial distress syndrome (PDS), has been introduced recently by the approval of Acotiamide, the first in class, muscarinic receptor antagonist & cholinesterase inhibitor. It has shown improvement in gastric motility in rodents & dogs and reduced PDS symptoms in patients in Double- blinded multicentric study.
Cited by 0
No indexed citations yet.
Related research
- Newer Aspects in Treatment of Irritable Bowel Syndrome: A Review — shares topic coverage
- Physiological Peculiarities of Hemocoagulation in Newborn Calves after Cresacin and Hamavit Application — shares topic coverage
- Prevalence of Helicobacter pylori Infection in Patients with Dyspeptic Symptoms in Damaturu Metropolitan — shares topic coverage
- Endoscopic Evaluation of Patients with Dyspepsia in a Tertiary Care Hospital in Bangladesh — shares topic coverage
- Digestive Disorders and Electrohomeopathy Approach — shares topic coverage
Article metrics
Real usage data collected on this platform.
4
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.